Get notified when TMDX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (worsened) — Material weakness in inventory movement controls remains unresolved; remediation controls implemented but not yet tested.
- Securities Litigation (worsened) — Securities class action advanced to discovery after partial denial of motion to dismiss.
TransMedics revenue up 20.7% to $189.9M, but net income falls 55.7% to $16.5M on surging R&D and HQ costs
Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 30, 2025 · ~1 min read
Key Changes
-
high
Revenue grew 20.7% to $189.9M, but net income dropped 55.7% to $16.5M as operating expenses nearly doubled.
MD&A verify on EDGAR → -
high
Operating income fell, driven by a 98% jump in R&D expense for next-gen OCS and OCS Kidney development.
MD&A verify on EDGAR → -
high
New Somerville HQ finance lease adds right-of-use asset and liability; total capex estimated at -240M through 2030.
Notes view on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade TMDX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 11, 2026 · How we verify